SUBSCRIBE
SUBSCRIBE
News   Business

Ipsen’s First Quarter 2007 Sales

May 3, 2007 | 
1 min read
+7.0% Growth in Group Sales, +9.4% Growth in Volume Sold Strong Dynamics in Strategic Targeted Therapeutic Areas: +12.8% Solid Growth Outside the Five Major Western European Countries: +20.7%
Earnings Europe
Ipsen Biopharmaceuticals, Inc.
MORE ON THIS TOPIC
Blank paper notes attached by adhesive tape, white background, vector eps10 illustration
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
 · 
2 min read
 · 
Gabrielle Masson
Approved and confirmed document file with check mark icon flat cartoon, concept of agreement or contract symbol with checkmark, accepted or certified license paper form pictogram isolated image
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
 · 
2 min read
 · 
Jef Akst
A man and woman on opposite edges of a large chat bubble
Insights
Golden Triangle still dominates, but talent and capital gaps slow biotech growth
July 1, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker